Announcement PDF ASX Announcement Enlitic, Inc. ARBN 672 254 027 1 29 October 2026 Quarterly Activity Report & Appendix 4C Q3 FY26 Highlights • Ensight commercial traction: Annualised recurring revenue (“ARR”) of ~US$760k at 30 September 2026, with Ensight live or contracted in the US, New Zealand and Australia, with a further ~US$360k waiting to go-live. • RIA Go-Live: Ensight went live at Radiology Imaging Associates, a Colorado based physician owned radiology group further validating Enlitic's Intelerad integration in a live production environment. • RCI Go-Live: Within a month of the RIA go-live, there was a second US Intelerad deployment at Radiology Consultants of Iowa. • University of Michigan Migration: US$806k migration project with University of Michigan Health – Sparrow for approximately ~10.6 million studies incorporating Ensight standardisation. The project is expected to be completed within 12 months. • Ensight v2.3 (post quarter-end): Released Ensight v2.3, expanding the platform from 8 to 12 commercial applications and adding Sectra as a second major OEM integration alongside Intelerad. • Contract execution and pipeline: 10 new client agreements signed, with total contract value of ~US$1.0m / ~A$1.4m1 . While contract values can vary quarter to quarter due to the timing and size of individual agreements, the underlying trajectory remains positive, supported by increasing Ensight deployments, go- lives and new customer wins. • Placement: Finalisation of a ~A$15m placement and, per the Company's current expectations, funds raised from the placement should be sufficient to fund operations through to cashflow break-even. • SPP: Completion of its non-underwritten Security Purchase Plan raising ~A$739k. • Convertible note conversion: Noteholders converted existing convertible notes into CDIs to simplify the capital structure and move to a debt-free balance sheet. 1 US$1.0m converted based on a USD:AUD exchange rate of 0.7061, being the average exchange rate for Q3 FY26. The average USD:AUD exchange rate for Q2 FY26 was 0.7098. Enlitic, Inc. ARBN 672 254 027 2 • Cost discipline: Enlitic maintained quarterly operating expenditure at US$3.0m (Q2 FY26: US$3.0m) and will continue to manage its monthly cash burn. • Cash receipts: US$0.55m for the quarter (Q2 FY26: US$2.3m). • Cash flow: Net operating cash outflow of US$2.45m, reflected the timing of customer receipts. • Consolidation of Capital: Completion of consolidation/reverse split of the Company’s issued capital on a ten (10) to one (1) basis. A medical technology software company leveraging artificial intelligence to improve the management and utility of medical imaging data, Enlitic, Inc. (ASX: ENL) (“Enlitic” or “the Company”), is pleased to provide this Quarterly Activity Report and Appendix 4C for the quarter ended 30 September 2026 (“Q3 FY26”). Please view the announcement here on our website: https://enlitic.com/link/Pb6W8P Michael Sistenich, CEO of Enlitic, said: “During the quarter, we continued to advance the commercial deployment of our Ensight platform. The successful go-lives at Radiology Imaging Associates and Radiology Consultants of Iowa mark further progress in our Intelerad partnership, demonstrating our ability to deploy Ensight across multiple customers in live production environments. Our US$806,000 migration contract with University of Michigan Health – Sparrow, incorporating Ensight standardisation across approximately 10.6 million studies, reinforces the strength of our integrated migration and data standardisation offering. Importantly, it demonstrates how we can leverage our migration capabilities to introduce customers to the broader Ensight platform. Ensight annualised recurring revenue reached US$760,000 at quarter end, with a further ~US$360k in process. Post quarter-end, the release of Ensight v2.3 took the platform from 8 to 12 commercial applications and added Sectra integration, giving us more to sell to each customer and access to more imaging environments. With Ensight live or contracted in the US, New Zealand and Australia, and our technology meeting applicable regulatory requirements across key markets, Enlitic has established a commercial and regulatory foundation from which to scale. We continue to strengthen our OEM partnerships and direct customer relationships, creating opportunities for larger enterprise contracts and recurring software revenue. Contract values will remain lumpy at our stage given the timing and mix of larger enterprise migration projects. Importantly, the underlying cadence of Ensight deployments is increasing. We have now demonstrated repeatable deployments through Intelerad, added Sectra as a second major OEM environment and have Ensight ARR of US$760,000. Each Enlitic, Inc. ARBN 672 254 027 3 deployment expands our annualised recurring revenue base while creating opportunities to introduce additional Ensight applications over time. Financially, we completed our A$15 million capital raising and A$739,000 Security Purchase Plan, alongside the conversion of our convertible notes, strengthening our balance sheet and eliminating our debt. We also maintained quarterly operating expenditure at ~US$3 million, demonstrating the sustained impact of the cost reductions implemented over the past year. While net operating cash outflow was higher this quarter due to the timing of receipts, cash burn continues to trend down, with year-to-date outflow ~25% lower than the same period last year. With our strengthened balance sheet, established OEM partnerships and growing number of live Ensight deployments, we have the financial and operational foundations to accelerate our commercial strategy. We enter the final quarter with a solid base of contracted revenue extending through the remainder of FY26 and into FY27, providing revenue visibility as we execute contracted migration projects and recurring Ensight subscriptions. Our priorities are to secure larger enterprise contracts, accelerate Ensight adoption and deliver our contracted migration projects, converting our operational capabilities into sustainable revenue growth.” Operational highlights Expanding Ensight deployments Enlitic expanded its Ensight production footprint during Q3 FY26, completing two additional customer go-lives through Intelerad. Radiology Imaging Associates (RIA), a Colorado-based, physician-owned radiology group, successfully deployed Ensight into its production environment. Another successful US deployment through the Intelerad channel with Radiology Consultants of Iowa (RCI) followed within a month. These deployments build on the earlier go-live at RHCNZ Medical Imaging Group in New Zealand. Three Ensight go-lives have now been completed through the Intelerad integration since May 2026, including two US deployments within a month during Q3. This demonstrates Enlitic's ability to repeat the deployment model across customers and markets, with deployment frequency increasing as the integration is rolled out. Enlitic continues to leverage its OEM partnerships to expand customer access, accelerate deployment and grow its recurring software subscription base. Enlitic, Inc. ARBN 672 254 027 4 Integrating Ensight into migration services Enlitic secured a US$806,000 migration contract with University of Michigan Health – Sparrow, combining Laitek's migration capabilities with Ensight data standardisation across ~10.6 million imaging studies. This approach reinforces Enlitic's strategy of using its migration business to introduce customers to the broader Ensight platform, creating opportunities for additional software adoption and recurring revenue. Ensight v2.3 and recurring revenue Ensight annualised recurring revenue (ARR) was ~US$760k at 30 September 2026, with a further ~US$360k waiting to go live. Post quarter-end, on 6 October 2026, Enlitic released Ensight v2.3, expanding the platform from 8 to 12 commercial applications. The four new applications are Productivity & Operational Analytics, Mass Archive Standardisation, Integrated Migration & Archive Standardisation and Standardised data for Automated Case Allocation. The release materially expands both what Enlitic can sell to each customer and where Ensight can be deployed. The four new applications are available to existing Ensight customers as additional subscriptions, increasing the potential recurring revenue from each customer on the same standardised data layer. Integrated Migration & Archive Standardisation allows Ensight to be embedded from the outset of a migration project, creating a direct pathway from project-based migration revenue to recurring software subscriptions. Sectra integration, being applied at University of Michigan Health-Sparrow, opens a second major OEM environment alongside Intelerad, with Sectra systems managing more than 170 million imaging examinations annually. A third major OEM integration is included in the release, subject to customer validation testing, which is currently completing final validation, with details expected before the end of 2026 Enlitic's technology meets applicable regulatory requirements across the US, UK, EU, New Zealand and Australia, and Ensight is now live or contracted with customers in the US, New Zealand and Australia. Together, this provides Enlitic with an established commercial and regulatory foundation from which to scale Ensight across multiple markets. Commercial Performance Enlitic advanced its OEM and direct sales activities during Q3 FY26, targeting larger enterprise migrations and broader Ensight adoption. Enlitic, Inc. ARBN 672 254 027 5 The Company signed 10 new customer agreements during the quarter (Q2 FY26: 17), generating total contract value (TCV) of ~US$1.0m (A$1.4m), broadly consistent with Q2 FY26 (US$1.0m / A$1.4m). The University of Michigan Health – Sparrow agreement accounted for the majority of new contract value during the quarter. Contract values remain lumpy from quarter to quarter given the timing and mix of larger enterprise migrations and smaller engagements. Enlitic continues to pursue larger enterprise opportunities through its established customer relationships and OEM channels, while the increasing cadence of Ensight deployments is expanding its recurring software revenue base. On a rolling 12-month basis, signed TCV totalled ~US$8.34m, compared with US$9.39m at the end of Q2 FY26. The decline reflects the lower value of contracts signed over the past two quarters. Enlitic is leveraging its OEM integrations and expanding customer base to pursue larger enterprise migration contracts, introduce Ensight into existing customer environments and grow recurring software revenue. Financial Performance & Cash Flow Summary Financial Performance Enlitic recorded unaudited revenue of ~US$0.9m during Q3 FY26, broadly consistent with Q2 FY26 (US$0.9m). Revenue recognition continues to reflect the timing of delivery milestones across the Company's migration projects and software subscriptions. 849 1,146 1,450 1,798 2,465 2,348 2,085 7,190 9,858 9,392 8,341 0 2000 4000 6000 8000 10000 12000 - 500 1,000 1,500 2,000 2,500 3,000 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Annual TCV $'000 Quarterly TCV US$'000 Customer Contracts: Moving Quarterly & Annual TCV Qtrly Moving Average Annual Moving Average Enlitic, Inc. ARBN 672 254 027 6 Continued cost discipline and efficiency Enlitic maintained its disciplined cost structure during Q3 FY26, with total operating expenditure of ~US$3.0m, consistent with Q2 FY26 (US$3.0m). The Company continues to realise the benefits of its cost reduction initiatives, maintaining quarterly expenditure ~36% below Q1 FY25 levels while supporting ongoing customer deployments, product development and commercial activities. Enlitic will maintain this cost discipline as it scales its migration business and Ensight subscriptions. Operating Cash Flow Cash receipts totalled US$0.6m during Q3 FY26, compared with US$2.3m in Q2 FY26. The reduction reflects the timing of customer collections, following significant receipts from contracts signed in prior periods during Q2. With operating expenditure remaining stable, the lower cash receipts drove a net operating cash outflow of US$2.5m for Q3 FY26, compared with US$0.7m in Q2 FY26. Over a longer period, cash burn continues to trend down. Average quarterly net operating cash outflow across Q2 and Q3 FY26 was ~US$1.6m, compared with ~US$3.1m across Q4 FY25 and Q1 FY26. Year-to-date net operating cash outflow of ~US$6.1m is ~25% lower than the same period in FY25 (~US$8.1m). 4,678 4,007 3,559 3,798 3,286 3,042 3,015 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 US $'000 Expenditure by Qtr - 25/26 Enlitic, Inc. ARBN 672 254 027 7 Enlitic is actively managing working capital and customer collections while driving contract execution and project delivery. Capital structure & funding During Q3 FY26, Enlitic completed its A$15 million placement, raising additional capital to support its commercial growth strategy and ongoing operations. The Company also completed its non-underwritten Security Purchase Plan (SPP), raising ~A$739,000, and converted its outstanding convertible notes into CDIs. Together, these transactions significantly strengthened Enlitic's balance sheet, eliminated its convertible note debt and provided additional financial flexibility to execute its strategy. Enlitic also completed the consolidation of its issued capital on a 10-for-1 basis during the quarter. Enlitic will leverage its strengthened balance sheet and reduced cost base to pursue larger enterprise contracts and expand Ensight adoption. Financial Outlook Enlitic enters Q4 FY26 with a strengthened balance sheet, a disciplined cost structure and an expanding base of live Ensight deployments. The Company enters Q4 FY26 with a solid base of contracted revenue extending through the remainder of FY26 and into FY27, providing revenue visibility from contracted migration projects, major enterprise programs and recurring Ensight subscriptions. This includes the University of Michigan Health-Sparrow project alongside Enlitic's broader portfolio of contracted customer programs. Revenue recognition will continue to reflect individual project delivery milestones and customer schedules. The Company will continue to drive commercial growth through its OEM partnerships and direct sales channels, targeting larger enterprise migration contracts and accelerating the adoption of Ensight across new and existing customers. (3,938) (3,290) (836) (3,324) (2,881) (698) (2,454) (5,000) (4,000) (3,000) (2,000) (1,000) 0 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 US $'000 Operating Cash Flow by Qtr - 25/26 Enlitic, Inc. ARBN 672 254 027 8 Operationally, Enlitic will focus on delivering contracted migration projects, expanding Ensight deployments and strengthening the integration of its migration and data standardisation capabilities to create additional recurring revenue opportunities. Enlitic will maintain its focus on cost discipline, working capital management and revenue growth as it progresses towards operational cash flow break-even. This announcement was authorised for release by the Board of Enlitic, Inc. – ENDS – Enquiries Enlitic Investor Relations Australia: invest_au@enlitic.com Henry Jordan Six Degrees Investor Relations +61 (0) 431 271 538 About Enlitic Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic’s products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at enlitic.com. Enlitic’s CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement. Forward-looking statements Enlitic, Inc. ARBN 672 254 027 9 Certain statements made during or in connection with this announcement contain or comprise certain forward-looking statements regarding the Company, its projected cash flow, financial performance, its customer contracts and customer pipeline and product development. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such expectations are only predictions and are subject to inherent risks and uncertainties which could cause actual values, results, performance or achievements to differ materially from those expressed, implied or projected in any forward-looking statements and no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of, among other factors, changes in economic and market conditions, delays or changes in product development and realisation of customer pipeline, changes in demand, success of business and operating initiatives, changes in the regulatory environment and other government actions, fluctuations in exchange rates and business and operational risk management. To the maximum extent permitted by law, each of the Company, its officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in these forward-looking statements and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in forward-looking statements or any error or omission. The Company undertakes no obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events other than required by the applicable laws, including the ASX Listing Rules. Accordingly, you should not place undue reliance on any forward-looking statement. Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 1 + See chapter 19 of the ASX Listing Rules for defined terms. Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Name of entity ENLITIC, INC. ABN Quarter ended (“current quarter”) ARBN 672 254 027 September 30 2026 Consolidated statement of cash flows Current quarter $US’000 Year to date (9 months) $US’000 1. Cash flows from operating activities 551 3,288 1.1 Receipts from customers 1.2 Payments for (821) (2,605) (a) research and development (b) product manufacturing and operating costs (249) (652) (c) advertising and marketing (101) (281) (d) leased assets - - (e) staff costs (1,310) (4,292) (f) administration and corporate costs (534) (1,513) 1.3 Dividends received (see note 3) 1.4 Interest received 10 22 1.5 Interest and other costs of finance paid - - 1.6 Income taxes paid 1.7 Government grants and tax incentives 1.8 Other (provide details if material) 1.9 Net cash from / (used in) operating activities (2,454) (6,033) 2. Cash flows from investing activities 2.1 Payments to acquire or for: (a) entities (b) businesses (c) property, plant and equipment (6) (10) (d) investments (e) intellectual property (f) other non-current assets Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 2 + See chapter 19 of the ASX Listing Rules for defined terms. Consolidated statement of cash flows Current quarter $US’000 Year to date (9 months) $US’000 2.2 Proceeds from disposal of: (a) entities (b) businesses (c) property, plant and equipment (d) investments (e) intellectual property (f) other non-current assets 2.3 Cash flows from loans to other entities 2.4 Dividends received (see note 3) 2.5 Other (provide details if material) 2.6 Net cash from / (used in) investing activities (6) (10) 3. Cash flows from financing activities 11,054 11,054 3.1 Proceeds from issues of equity securities (excluding convertible debt securities) 3.2 Proceeds from issue of convertible debt securities - 3,707 3.3 Proceeds from exercise of options 5 5 3.4 Transaction costs related to issues of equity securities or convertible debt securities (1,237) (1,963) 3.5 Proceeds from borrowings 3.6 Repayment of borrowings 3.7 Transaction costs related to loans and borrowings 3.8 Dividends paid 3.9 Other (provide details if material) 3.10 Net cash from / (used in) financing activities 9,822 12,803 4. Net increase / (decrease) in cash and cash equivalents for the period 2,052 2,569 4.1 Cash and cash equivalents at beginning of period 4.2 Net cash from / (used in) operating activities (item 1.9 above) (2,454) (6,033) 4.3 Net cash from / (used in) investing activities (item 2.6 above) (6) (10) 4.4 Net cash from / (used in) financing activities (item 3.10 above) 9,822 12,803 Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 3 + See chapter 19 of the ASX Listing Rules for defined terms. Consolidated statement of cash flows Current quarter $US’000 Year to date (9 months) $US’000 4.5 Effect of movement in exchange rates on cash held 39 124 4.6 Cash and cash equivalents at end of period 9,453 9,453 5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts Current quarter $US’000 Previous quarter $US’000 5.1 Bank balances 9,453 2,052 5.2 Call deposits 5.3 Bank overdrafts 5.4 Other (provide details) 5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above) 9,453 2,052 6. Payments to related parties of the entity and their associates Current quarter $US'000 6.1 Aggregate amount of payments to related parties and their associates included in item 1 - 6.2 Aggregate amount of payments to related parties and their associates included in item 2 139 Cash Paid for Directors and Non-Executive Directors in quarter 2 amounted to US$139k which includes salaries, travel and reimbursement of any costs. Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 4 + See chapter 19 of the ASX Listing Rules for defined terms. 7. Financing facilities Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity. Total facility amount at quarter end $US’000 Amount drawn at quarter end $US’000 7.1 Loan facilities - - 7.2 Credit standby arrangements - - 7.3 Other (please specify) - - 7.4 Total financing facilities - - 7.5 Unused financing facilities available at quarter end - 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. 8. Estimated cash available for future operating activities $US’000 8.1 Net cash from / (used in) operating activities (item 1.9) (2,454) 8.2 Cash and cash equivalents at quarter end (item 4.6) 9,453 8.3 Unused finance facilities available at quarter end (item 7.5) - 8.4 Total available funding (item 8.2 + item 8.3) 9,453 8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1) 3.85 Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5. 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions: 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: Not applicable 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: Not applicable 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: Not applicable Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered. Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B ASX Listing Rules Appendix 4C (17/07/20) Page 5 + See chapter 19 of the ASX Listing Rules for defined terms. Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. Date: 29 October 2026. Authorised by: the Board (Name of body or officer authorising release – see note 4) Notes 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so. 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report. 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity. 4. If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”. If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the [name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a disclosure committee, you can insert here: “By the Disclosure Committee”. 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.